Impact of the COVID-19 pandemic on the oncologic activities (diagnosis, treatment, clinical trials enrollment) of a general hospital in a district with high prevalence of SARS-COV-2 in Italy

• Published in: Supportive care in cancer Vol. 30; no. 4; pp. 3225 - 3231
• Main Authors: Ambroggi, Massimo, Citterio, Chiara, Vecchia, Stefano, Riva, Alessandra, Mordenti, Patrizia, Cavanna, Luigi
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.04.2022; Springer; Springer Nature B.V
• Subjects: Cancer; Clinical trials; Clinical Trials as Topic; Comparative analysis; Coronaviruses; COVID-19; Epidemics; Health aspects; Hospitals, General; Humans; Italy - epidemiology; Medical diagnosis; Medicine; Medicine & Public Health; Nursing; Nursing Research; Oncology; Oncology, Experimental; Oral cancer; Original; Original Article; Pain Medicine; Pandemics; Prevalence; Rehabilitation Medicine; Retrospective Studies; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; Italy; COVID-19; Cancer management; Clinical studies; Oral cancer treatment; Cancer
• ISSN: 0941-4355; 1433-7339
• DOI: 10.1007/s00520-021-06667-y

Purpose Little is known about the real impact of the COVID-19 outbreak on the qualitative and quantitative fall-out on the management of cancer patients. Our objective was to provide evidence of the effects of SARS-COV-2 on the management of cancer patients in the real world. Methods In a general hospital in a district in Italy with high prevalence of COVID-19 during the first wave, we retrospectively analyzed the data of oncologic activity, namely new cancer diagnosis, types of treatment (intravenous or by mouth), clinical research studies, and drug utilization, and compared the findings with those of 2019, before the pandemic. The data have been summarized in boxplot figures for median and interquartile range. Results In 2020, a significant reduction in new cancer diagnosis was demonstrated when compared with 2019, with 17.4% fewer cancer diagnoses, 84.5% fewer patients enrolled in clinical trials, a 10.6% reduction in intravenous antitumor treatment, and a 42.7% increase in oral anticancer treatment. Conclusion Our data indicate a significant reduction in cancer diagnosis, antitumor venous treatment, and patients enrolled in clinical research studies in 2020 compared with 2019, although there was a significant increase in oral treatment. These data suggest that the COVID-19 pandemic had a deep impact on the real-world management of cancer patients in a district of Italy with a high prevalence of COVID-19.